Felix Dietlein

Dr. Felix Dietlein

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FDFelix Dietlein
Felix Dietlein
DWDonate Weghorn
Donate Weghorn
ATAmaro Taylor-Weiner
Amaro Taylor-Weiner
ARAndré Richters
André Richters
BRBrendan Reardon
Brendan Reardon
SSShamil R. Sunyaev
Shamil R. Sunyaev

8 April 2022 in Science
Verified
Journal Article
Closed access
FDFelix Dietlein
Felix Dietlein
AWAlex B. Wang
Alex B. Wang
CFChristian Fagre
Christian Fagre
ATAnran Tang
Anran Tang
NBNicolle J. M. Besselink
Nicolle J. M. Besselink
EAEliezer Van Allen
Eliezer Van Allen
We established a genome-wide compendium of somatic mutation events in 3949 whole cancer genomes representing 19 tumor types. Protein-coding events captured well-established drivers. Noncoding events near tissue-specific genes, such as ALB in the liver or KLK3 in the prostate, characterized localized passenger mutation patterns and may reflect tumor-cell-of-origin imprinting. Noncoding events in regulatory promoter and enhancer regions frequently involved cancer-relevant genes such as BCL6 , FGFR2 , RAD51B , SMC6 , TERT , and XBP1 and represent possible drivers. Unlike most noncoding regulatory events, XBP1 mutations primarily accumulated outside the gene’s promoter, and we validated their effect on gene expression using CRISPR-interference screening and luciferase reporter assays. Broadly, our study provides a blueprint for capturing mutation events across the entire genome to guide advances in biological discovery, therapies, and diagnostics.

20 June 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MSMaxwell A. Sherman
Maxwell A. Sherman
AYAdam U. Yaari
Adam U. Yaari
OPOliver Priebe
Oliver Priebe
FDFelix Dietlein
Felix Dietlein
PLPo-Ru Loh
Po-Ru Loh
BBBonnie Berger
Bonnie Berger
Identification of cancer driver mutations that confer a proliferative advantage is central to understanding cancer; however, searches have often been limited to protein-coding sequences and specific non-coding elements (for example, promoters) because of the challenge of modeling the highly variable somatic mutation rates observed across tumor genomes. Here we present Dig, a method to search for driver elements and mutations anywhere in the genome. We use deep neural networks to map cancer-specific mutation rates genome-wide at kilobase-scale resolution. These estimates are then refined to search for evidence of driver mutations under positive selection throughout the genome by comparing observed to expected mutation counts. We mapped mutation rates for 37 cancer types and applied these maps to identify putative drivers within intronic cryptic splice regions, 5′ untranslated regions and infrequently mutated genes. Our high-resolution mutation rate maps, available for web-based exploration, are a resource to enable driver discovery genome-wide.

13 August 2018 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
MHM. Hohberg
M. Hohberg
CKCarsten Kobe
Carsten Kobe
PTP. Täger
P. Täger
JHJ. Hammes
J. Hammes
MSMatthias Christian Schmidt
Matthias Christian Schmidt
MDMarkus Dietlein
Markus Dietlein

23 April 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
LMLydia Meder
Lydia Meder
COCharlotte Isabelle Orschel
Charlotte Isabelle Orschel
COChristoph Julius Otto
Christoph Julius Otto
MKMirjam Koker
Mirjam Koker
JBJohannes Brägelmann
Johannes Brägelmann
RURoland Tillmann Ullrich
Roland Tillmann Ullrich
Small cell lung cancer (SCLC) is the most aggressive lung cancer entity with an extremely limited therapeutic outcome. Most patients are diagnosed at an extensive stage. However, the molecular mechanisms driving SCLC invasion and metastasis remain largely elusive. We used an autochthonous SCLC mouse model and matched samples from patients with primary and metastatic SCLC to investigate the molecular characteristics of tumor metastasis. We demonstrate that tumor cell invasion and liver metastasis in SCLC are triggered by an Angiopoietin-2 (ANG-2)/Integrin β-1–dependent pathway in tumor cells, mediated by focal adhesion kinase/Src kinase signaling. Strikingly, CRISPR-Cas9 KO of Integrin β-1 or blocking Integrin β-1 signaling by an anti–ANG-2 treatment abrogates liver metastasis formation in vivo. Interestingly, analysis of a unique collection of matched samples from patients with primary and metastatic SCLC confirmed a strong increase of Integrin β-1 in liver metastasis in comparison with the primary tumor. We further show that ANG-2 blockade combined with PD-1–targeted by anti-PD-1 treatment displays synergistic treatment effects in SCLC. Together, our data demonstrate a fundamental role of ANG-2/Integrin β-1 signaling in SCLC cells for tumor cell invasion and liver metastasis and provide a potentially new effective treatment strategy for patients with SCLC.

28 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
KSKlaus Schomäcker
Klaus Schomäcker
FDFelix Dietlein
Felix Dietlein
SVSergio Muñoz Vázquez
Sergio Muñoz Vázquez
FBFeodor Braun
Feodor Braun
TFThomas Fischer
Thomas Fischer
MDMarkus Dietlein
Markus Dietlein
The interdisciplinary possibilities inherent in nuclear medicine offer an opportunity for the patient-centered development of radioactive pharmaceuticals based on specific research questions. This approach provides radiopharmaceutical manufacturers with a robust scientific foundation on which to navigate the regulatory requirements for drug approval laid down by the law. A vivid illustration of this interdisciplinary cooperation has been the development of a Zr-89-labeled PSMA ligand where reliable results have been obtained across various domains, including chemistry, radiochemistry, biochemistry, and preclinical research. This comprehensive process extended to feasibility studies conducted with carefully selected patients from a single nuclear medicine clinic. The approach demonstrates how far close collaboration between different disciplines within nuclear medicine can further the move towards patient-oriented radiopharmaceutical treatments while simultaneously meeting regulatory demands. With such a strategy, innovative radiopharmaceutical solutions can be brought to the market more swiftly and efficiently, in line with the needs of patients.